Contrast-Enhanced Ultrasound for Cervical Cancer
Trial Summary
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you have received an investigational drug in the 30 days before the study or will receive one within 72 hours afterwards, you cannot participate.
What data supports the idea that Contrast-Enhanced Ultrasound for Cervical Cancer is an effective treatment?
The available research shows that Contrast-Enhanced Ultrasound (CEUS) is useful in assessing cervical cancer. For example, one study found that CEUS can help predict how well a cervical tumor will respond to chemotherapy. Another study showed that CEUS, when combined with regular ultrasound, is reliable for staging cervical cancer, which means it helps doctors understand how advanced the cancer is. These findings suggest that CEUS is effective in helping manage cervical cancer by providing important information about the tumor and its response to treatment.12345
What safety data exists for Sonazoid (perflubutane) in clinical trials?
Is contrast-enhanced ultrasound a promising treatment for cervical cancer?
Yes, contrast-enhanced ultrasound is a promising treatment for cervical cancer. It helps doctors see the cancer more clearly, which can improve how they stage and treat the disease. It can also predict how well a tumor will respond to chemotherapy, making it a valuable tool in managing cervical cancer.1251112
What is the purpose of this trial?
This clinical trial compares the use of ultrasound for the detection of sentinel lymph nodes (SLNs) to the standard of care (which varies depending on cancer treatment). The ultrasound contrast agent is called Sonazoid and it consists of tiny gas-filled bubbles about the side of red blood cells. Diagnostic procedures, such as ultrasound with Sonazoid, may help identify more SLNs than standard of care in patients with cervical, vaginal, or vulvar cancer.
Eligibility Criteria
This trial is for women over 18 with cervical, vaginal, or vulvar cancer who can follow study procedures. They must not be pregnant/nursing and have no recent surgeries, unstable heart conditions, severe allergies to Sonazoid/eggs, or been on life support recently.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic Procedure
Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Sonazoid
Find a Clinic Near You
Who Is Running the Clinical Trial?
Thomas Jefferson University
Lead Sponsor
National Cancer Institute (NCI)
Collaborator